Neurocrine Biosciences Presents New INGREZZA Capsules Data Demonstrating Early And Sustained Improvements In Chorea Associated With Huntington's Disease
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has presented new data on its INGREZZA capsules at the 2023 MDS International Congress of Parkinson's Disease and Movement Disorders. The data shows early and sustained improvements in chorea associated with Huntington's disease.
August 28, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences' new data on INGREZZA capsules demonstrates early and sustained improvements in Huntington's disease-associated chorea. This could potentially boost the company's reputation and sales.
The new data presented by Neurocrine Biosciences on its INGREZZA capsules shows promising results in treating Huntington's disease-associated chorea. This positive news could potentially increase the company's reputation in the healthcare sector and boost sales of the product, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100